

1 **Tocilizumab and sarilumab alone or in combination with**
2 **corticosteroids for COVID-19: A systematic review and network meta-**
3 **analysis**

- 4 Dena Zeraatkar, methodologist
5 Department of Biomedical Informatics, Harvard Medical School
6 Department of Health Research Methods, Evidence, and Impact, McMaster University
7
8 Ellen Cusano, internist
9 Cumming School of Medicine, University of Calgary
10
11 Juan Pablo Díaz Martinez, methodologist
12 Department of Health Research Methods, Evidence, and Impact, McMaster University
13
14 Anila Qasim, methodologist
15 Department of Health Research Methods, Evidence, and Impact, McMaster University
16
17 Sophia O. Mangala, methodologist
18 Department of Health Research Methods, Evidence, and Impact, McMaster University
19
20 Elena Kum, methodologist
21 Department of Health Research Methods, Evidence, and Impact, McMaster University
22
23 Jessica J. Bartoszko, methodologist
24 Department of Health Research Methods, Evidence, and Impact, McMaster University
25
26 Tahira Devji, methodologist
27 Department of Health Research Methods, Evidence, and Impact, McMaster University
28
29 Thomas Agoritsas, internist, methodologist
30 Department of Health Research Methods, Evidence, and Impact, McMaster University
31 Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of
32 Geneva, Geneva
33 MAGIC Evidence Ecosystem Foundation, Oslo
34
35 Francois Lamontagne, critical care physician, methodologist
36 Department of Medicine, University of Sherbrooke, Sherbrooke, Quebec
37 Centre de recherche du CHU University of Sherbrooke, Sherbrooke, Quebec
38
39 Bram Rochweg, critical care physician, methodologist
40 Department of Health Research Methods, Evidence, and Impact, McMaster University
41 Department of Medicine, McMaster University
42
43 Per O Vandvik, internist, methodologist

44 MAGIC Evidence Ecosystem Foundation, Oslo
45 Department of Health Economics and Health Management, Institute for Health and Society,
46 University of Oslo, Oslo

47
48 Romina Brignardello-Petersen, methodologist
49 Department of Health Research Methods, Evidence, and Impact, McMaster University

50
51 Reed Siemieniuk*, internist, methodologist
52 Department of Health Research Methods, Evidence, and Impact, McMaster University

53
54 *Corresponding author: Reed Siemieniuk (reed.siemieniuk@medportal.ca)

55 **Disclaimers:** None

56 **Funding:** This project is supported by two CIHR Operating Grants (VR4- 172738; MM1- 174897).

57 **Data:** Data is available in the supplementary materials.

58 **Authors' Contributions:** DZ, BR, FL, TA, POV, RBP, and RS conceived the study. JB identified studies. DZ,
59 EC, and EK collected the data. AQ and JPDM analyzed the data. TD and RBP assessed the certainty of
60 evidence. DZ drafted the first version of this manuscript.

61 **Word count:** 2,580

62

63

64 **Abstract**

65

66 **Objective:** To compare the effects of interleukin-6 (IL-6) receptor blockers, with or without
67 corticosteroids, on mortality in patients with COVID-19.

68 **Design:** Systematic review and network meta-analysis

69 **Data sources:** WHO COVID-19 database, a comprehensive multilingual source of global covid-19
70 literature, and two prospective meta-analyses

71 **Study selection:** Trials in which people with suspected, probable, or confirmed COVID-19 were
72 randomized to IL-6 receptor blockers (with or without corticosteroids), corticosteroids, placebo, or
73 standard care.

74 **Results:** We assessed the risk of bias of included trials using a modification of the Cochrane risk of bias
75 2.0 tool. We performed a Bayesian fixed effect network meta-analysis and assessed the certainty of
76 evidence using the GRADE approach.

77 We identified 45 eligible trials (20,650 patients), 36 (19,350 patients) of which could be included in the
78 network meta-analysis. 27 of 36 trials were rated at high risk of bias, primarily due to lack of blinding.
79 Tocilizumab (20 more per 1000, 15 fewer to 59 more; low certainty) and sarilumab (11 more per 1000,
80 38 fewer to 55 more; low certainty) alone may not reduce the risk of death. Tocilizumab, in combination
81 with corticosteroids, probably reduces the risk of death compared to corticosteroids alone (35 fewer per
82 1000, 52 fewer to 18 more; moderate certainty) and sarilumab, in combination with corticosteroids,
83 may reduce the risk of death compared to corticosteroids alone (43 fewer, 73 fewer to 12 more; low
84 certainty). Tocilizumab and sarilumab, both in combination with corticosteroids, may have similar
85 effects (8 more per 1000, 20 fewer to 35 more; low certainty).

86 **Conclusion:** IL-6 receptor blockers, when added to standard care that includes corticosteroids, in
87 patients with severe or critical COVID-19, probably reduce mortality. Tocilizumab and sarilumab may
88 have similar effectiveness.

89 **Systematic review registration:** NA

90

91 **What is already known on this topic?**

- 92 • IL-6 receptor blockers have immunosuppressive effects that may be important in COVID-19
93 patients with immune system dysfunction and inflammation
94 • Corticosteroids reduce the risk of death in patients with severe or critical COVID-19

95 **What this study adds**

- 96 • Our systematic review and network meta-analysis provides a comprehensive review of the
97 evidence addressing the effects of IL-6 receptor blockers, alone or in combination with
98 corticosteroids, in COVID-19
99 • IL-6 receptor blockers when added to a standard care that includes corticosteroids, in patients
100 with severe or critical COVID-19, probably reduce mortality.
101 • Tocilizumab and sarilumab in combination with corticosteroids may have similar effectiveness
102 for reducing mortality.

103

104 **Background**

105 As of June 2021, there have been more than 180 million cumulative cases of coronavirus disease 19
106 (COVID-19) worldwide and nearly four million deaths (1). In an attempt to improve outcomes for patients
107 with COVID-19, several drugs have been repurposed with varying results (2). Corticosteroids are the only
108 medication so far to have reduced mortality in patients with severe and critical disease (2). Tocilizumab,
109 an interleukin-6 (IL-6) receptor blocker may also reduce mortality, but whether sarilumab (another IL-6
110 receptor blocker) reduces mortality is uncertain.

111 IL-6 receptor blockers have immunosuppressive effects that may be important in COVID-19 patients with
112 immune system dysfunction and inflammation (3-5). The RECOVERY trial found that tocilizumab reduces
113 mortality and ventilation, particularly among patients receiving corticosteroids (6) and REMAP-CAP
114 showed tocilizumab and sarilumab to reduce mortality and improve organ-support free days (7). Results
115 across other trials, however, have not been consistent (8-10). A prospective meta-analysis also found that
116 tocilizumab reduces mortality (11), but whether sarilumab reduces mortality compared to no IL-6 receptor
117 blocker, and its effect relative to tocilizumab is unclear.

118 Tocilizumab is an expensive drug to which patients with COVID-19 currently have access—in settings
119 where it is available, tocilizumab is often used in only a minority of patients who might benefit from it
120 (12). If sarilumab is a comparable alternative to tocilizumab, it would increase availability for patients with
121 COVID-19 who would not have otherwise have access to IL-6 receptor blocker.

122 Here we report a systematic review and network meta-analysis addressing the effectiveness of IL-6
123 receptor blockers, alone or in combination with corticosteroids, for COVID-19. This review capitalizes on
124 the methods and data of our living systematic review and network meta-analysis of drug therapies for
125 COVID-19 (2). This evidence synthesis is part of the BMJ Rapid Recommendations project, to inform World
126 Health Organization (WHO) Living Guidelines on drugs for treatment of COVID-19 (13).

127 **Methods**

128 A protocol of our methods is contained as a supplement to our living systematic review and network meta-
129 analysis (SRNMA) of drug therapies for COVID-19 (2).

130 **Search**

131 Our study uses the search strategy of our living SRNMA that includes daily searches in the World Health
132 Organization (WHO) COVID-19 database—a comprehensive multilingual source of global published and
133 preprint literature on COVID-19 (<https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019->

134 ncov/). Prior to its merge with the WHO COVID-19 database on 9 October 2020, we searched the US
135 Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database.
136 The database includes, but is not limited to the following bibliographic and grey literature sources:
137 Medline (Ovid and PubMed), PubMed Central, Embase, CAB Abstracts, Global Health, PsycInfo, Cochrane
138 Library, Scopus, Academic Search Complete, Africa Wide Information, CINAHL, ProQuest Central,
139 SciFinder, the Virtual Health Library, LitCovid, WHO covid-19 website, CDC covid-19 website,
140 Eurosurveillance, China CDC Weekly, Homeland Security Digital Library, ClinicalTrials.gov, bioRxiv
141 (preprints), medRxiv (preprints), chemRxiv (preprints), and SSRN (preprints). Our search also includes six
142 Chinese databases: Wanfang, Chinese Biomedical Literature, China National Knowledge Infrastructure,
143 VIP, Chinese Medical Journal Net (preprints), and ChinaXiv (preprints). A validated machine learning model
144 facilitates efficient identification of randomized trials (14). We searched WHO information sources from
145 1 December 2019 to 9 June 2021 and the Chinese literature from conception of the databases to 20
146 February 2021.

147 Our search is supplemented by ongoing surveillance of living evidence retrieval services, including the
148 Living Overview of the Evidence (L-OVE) COVID-19 platform by the Epistemonikos Foundation
149 (<https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d>) and the Systematic and Living Map
150 on COVID-19 Evidence by the Norwegian Institute of Public Health ([https://www.fhi.no/en/qk/systematic-
151 reviews-hta/map/](https://www.fhi.no/en/qk/systematic-reviews-hta/map/)).

152 In addition, we include data directly from trialists via two WHO-sponsored prospective meta-analyses (11,
153 15). We report our full strategy as a supplement to our drug therapy publication (2).

154 ***Study selection***

155 As part of the living SRNMA, pairs of reviewers, following calibration exercises, worked independently and
156 in duplicate to screen titles and abstracts of search records and subsequently the full texts of records
157 determined potentially eligible at the title and abstract screening stage and to link preprint reports with
158 their subsequent publications based on trial registration numbers, authors, and other trial characteristics.
159 Reviewers resolved discrepancies by discussion, and when necessary, by adjudication with a third-party
160 reviewer.

161 We included preprint and peer reviewed reports of trials that compared IL-6 receptor blockers with
162 standard care, placebo, or corticosteroids or that compared corticosteroids with standard care or placebo
163 in patients with suspected, probable, or confirmed COVID-19. There were no restrictions on severity of
164 illness, setting, or language of publication.

165 **Data collection**

166 As part of the living SRNMA, for each eligible trial, pairs of reviewers, following training and calibration
167 exercises, independently extracted trial characteristics (trial registration, publication status, study design),
168 patient characteristics (country, age, sex, type of care, severity of COVID-19 symptoms), and outcomes of
169 interest (means or medians and measures of variability for continuous outcomes and the number of
170 participants analyzed and the number of participants who experienced an event for dichotomous
171 outcomes) using a standardized, pilot tested data extraction form. Reviewers resolved discrepancies by
172 discussion and, when necessary, with adjudication by a third party. We updated our data when a study
173 preprint becomes available as a peer reviewed publication. For this review, we focus on all-cause mortality
174 closest to 90 days.

175 To assess risk of bias, reviewers, following training and calibration exercises, use a revision of the Cochrane
176 tool for assessing risk of bias in randomized trials (RoB 2.0) (16). We present our modified risk of bias tool
177 as a supplement to our drug therapy publication (2). Reviewers resolved discrepancies by discussion and,
178 when necessary, by adjudication with a third party.

179 **Analysis**

180 We performed network meta-analysis using a Bayesian framework to compare tocilizumab with and
181 without corticosteroids, sarilumab with and without corticosteroids, corticosteroids without IL-6 receptor
182 blockers, and standard care or placebo. We used a plausible prior for the variance parameter and a
183 uniform prior for the effect parameter (17). We used three Markov chains with 100,000 iterations after
184 an initial burn-in of 10,000 and a thinning of 10. We used node splitting models to assess local incoherence
185 and to obtain indirect estimates. All network meta-analyses were performed using the gemtc package of
186 R version 3.6.3 (RStudio, Boston, MA) and all pairwise meta-analyses using the bayesmeta package. We
187 produced network plots using the network map command of Stata version 17.0 (StataCorp, College
188 Station, TX) with nodes weighted by the number of studies evaluating each treatment and edges weighted
189 by the inverse variance of the direct estimate (18).

190 We present fixed-effect meta-analyses as the primary analysis and random-effects meta-analyses as
191 sensitivity analysis because we found the estimates from random-effects to have credible intervals that
192 were implausibly wide due to the uncertainty around the heterogeneity estimate.

193 We summarized the effect of interventions on mortality using odds ratios and corresponding 95% credible
194 interval.

195 ***Certainty of evidence***

196 To facilitate interpretation of the results, we calculated absolute effects for mortality using data from the
197 CDC on patients who were hospitalized for COVID-19 (19, 20). For duration of ventilation, we used
198 baseline risks from the International Severe Acute Respiratory and Emerging Infection COVID-19 database
199 (21).

200 We assessed the certainty of evidence using GRADE approach for network meta-analysis, using a
201 minimally contextualized approach, with a null effect as the threshold of importance (22-25). The
202 minimally contextualized approach considers only whether credible intervals include the null effect and
203 thus does not consider whether plausible effects, captured by credible intervals, include both important
204 and trivial effects. To evaluate certainty of no benefit (or no effect), we used a 1% risk difference threshold
205 of the 95% credible interval for mortality. We decided on this preliminary threshold based on a survey of
206 the authors.

207 Two reviewers with experience in applying the GRADE approach rated each domain for each comparison
208 separately and resolved discrepancies by consensus. We rated the certainty for each comparison and
209 outcome as high, moderate, low, or very low, based on considerations of risk of bias, inconsistency,
210 indirectness, publication bias, intransitivity, incoherence (difference between direct and indirect effects),
211 and imprecision. We rated down for risk of bias if the interpretation of the effect would change if only
212 studies at low risk of bias would have been considered. For example, if the credible interval of the pooled
213 effect from studies at low risk of bias would have crossed the threshold for imprecision, we rated down
214 for risk of bias.

215 ***Patient and public involvement***

216 Patients were involved in outcome selection, interpretation of results, and the generation of parallel
217 recommendations, as part of the WHO Rapid Recommendations initiative, in partnership with The BMJ
218 and MAGIC Evidence Ecosystem Foundation.

219 **Results**

220 ***Study characteristics***

221 We screened 45,854 titles and abstracts and 884 full-texts and identified 45 eligible trials, including 20,650
222 patients (6, 26-48). Figure 1 presents details about study selection. Twenty-one of these trials were
223 published, four were available as preprints, and 20 were unpublished and were retrieved from two
224 prospective meta-analyses (11, 49).

225 Table 1 presents trial characteristics. Twenty trials (7,608 patients) compared tocilizumab with standard
226 care or placebo, (6, 26-34) seven trials (2,756 patients) sarilumab with standard care or placebo with or
227 without corticosteroids,(35, 36) three trials (366 patients) compared IL-6 receptor blockers with
228 corticosteroids (48), and 14 trials (8,102 patients) corticosteroids with standard care or placebo (37-47).

229 One trial, REMAP-CAP (7), randomized patients to tocilizumab or standard care (among centres with
230 access to tocilizumab) or to sarilumab or standard care (among centres with access to sarilumab).
231 Randomization to standard care was halted midway through the trial when an interim analysis showed
232 efficacy of tocilizumab and sarilumab after which patients were randomized to either tocilizumab or
233 sarilumab, with both groups receiving corticosteroids. We treated REMAP-CAP as three separate trials in
234 our analyses (i.e., tocilizumab versus standard care; sarilumab versus standard care; tocilizumab versus
235 sarilumab). We used 90-day mortality for the comparisons of tocilizumab and sarilumab with standard
236 care and obtained data on in-hospital mortality from the investigators of the trial on the comparison of
237 tocilizumab and sarilumab.

238 Another trial, Sarilumab-COVID-19, was conducted in two phases (35). Phase three underwent two
239 protocol amendments involving patient eligibility and dose. The trial was thus treated as four separate
240 trials.

241 ***Patient characteristics***

242 Table 1 presents characteristics of patients included in the trial. Trials included a median of 129 [IQR: 47
243 to 354] participants. The mean age of patients in trials ranged between 42.1 to 69.8. About half of all
244 patients were recruited from the United Kingdom. All but one trial reported on inpatients. Almost all trials
245 reported on patients with severe to critical disease and most patients were receiving some form of
246 supplementary oxygen.

247 ***Risk of bias***

248 Figure 3 presents risk of bias assessments for the trials that were included in the analysis. Nine trials
249 (including 3801 participants) were rated as low risk of bias the remainder (27 trials; 15,549 participants)
250 were at high risk of bias—primarily due to lack of blinding.

251 ***Mortality***

252 We included 36 trials, with 19,350 patients and 5,269 deaths, in our network comparing tocilizumab and
253 sarilumab, with or without corticosteroids, and corticosteroids in comparison with standard care or
254 placebo (6, 26-28, 30, 31, 34, 35, 37-40, 42-46, 48). Nine trials could not be included in the analysis because
255 they did not report outcome data, or, for trials that compared IL-6 receptor blockers with standard care

256 or placebo, we could not retrieve subgroup data based on concomitant treatment with corticosteroids
257 (29, 32, 33, 36, 41, 47). Figure 2 presents the network plot. Supplementary 1 contains data for the network
258 meta-analysis.

259 Table 2 presents results from the network meta-analysis. Tocilizumab and sarilumab alone may not reduce
260 mortality compared to standard care and corticosteroids probably reduce the risk of death. Compared to
261 corticosteroids alone, tocilizumab in combination with corticosteroids probably reduces mortality and
262 sarilumab in combination with corticosteroids may reduce mortality. In combination with corticosteroids,
263 sarilumab may have similar effects to tocilizumab in reducing mortality. Supplementary 2 presents all
264 direct and indirect comparisons and their certainty of evidence.

265 Supplementary 3 presents results from the random-effects model. Results from the random-effects model
266 were largely consistent with results from the fixed-effects model—though the random-effects model
267 produced effect estimates that were more imprecise due to incorporation of an additional heterogeneity
268 parameter in the model.

269 **Discussion**

270 ***Main findings***

271 This systematic review and network meta-analysis provides a comprehensive overview of the evidence
272 for IL-6 receptor blockers, alone or in combination with corticosteroids. We show that IL-6 receptor
273 blockers, when added to a standard care that includes corticosteroids, in patients with severe or critical
274 COVID-19, probably reduce mortality. Whether or not IL-6 receptor blockers have any impact on mortality
275 without concomitant use of corticosteroids remains uncertain. Sarilumab appears to have similar
276 effectiveness as tocilizumab.

277 ***Findings in context***

278 Our findings are consistent with a prospective meta-analysis (11), and the largest trials on IL-6 receptor
279 blockers, RECOVERY and REMAP-CAP (6, 7). Though several smaller trials did not find a benefit with
280 tocilizumab, the totality of the evidence suggests that this is probably because smaller individual trials
281 were underpowered to detect such a modest reduction in mortality.

282 Our study adds to the evidence base by showing that IL-6 receptor blockers may reduce mortality when
283 added to a standard care regimen that includes corticosteroids and that sarilumab may have a similar
284 effect on mortality as tocilizumab. This result is largely driven by the component of the REMAP-CAP trial
285 that directly compared sarilumab to tocilizumab.

286 ***Strengths and limitations***

287 The strengths of this review include the comprehensive search and screening strategy. In addition to trials
288 that we identified as part of our own search, we also included trials from two prospective meta-analyses
289 that included an inception cohort of registered trials thereby minimizing the effects of publication bias
290 (11, 15).

291 Our findings are limited by the risk of bias of the trials, the majority of which were at high risk of bias due
292 to lack of blinding. Lack of blinding may introduce bias through differences in co-interventions between
293 randomized groups. We took a conservative approach and rated down the certainty of evidence for risk
294 of bias. Some, including the linked WHO guideline panel, did not consider lack of blinding to be a serious
295 concern for mortality, because it is an objective outcome (13).

296 We only considered corticosteroid use at the time of randomization and some patients probably received
297 corticosteroids after randomization, but were considered in this review not to have received concomitant
298 corticosteroids. Whether or not IL-6 receptor blockers reduce mortality when not co-administered with
299 corticosteroids remains uncertain.

300 Four trials that we included in our systematic review were only available as preprint publications. Including
301 preprints in meta-analyses may increase the precision of estimates, allow timely dissemination, and may
302 minimize the effects of publication bias. It may, however, reduce the credibility of evidence syntheses and
303 risk serious errors if important differences appear in later published reports. As part of our living
304 systematic review and network meta-analysis, we have been maintaining a comprehensive comparison
305 of differences in key methods and results between preprints and publications. Differences between
306 preprints and peer reviewed publications have mostly been limited to baseline patient characteristics and
307 any changes we have observed so far would not have resulted in a meaningful change to the pooled effect
308 estimates or certainty of evidence (2).

309 **Conclusion**

310 Evidence from this systematic review and network meta-analysis shows that IL-6 receptor blockers when
311 added to a standard care that includes corticosteroids, in patients with severe or critical COVID-19,
312 probably reduce mortality. The available evidence suggests that tocilizumab and sarilumab may be
313 similarly effective. Our findings support linked WHO guidelines on IL-6 receptor blockers, which
314 recommends using either tocilizumab or sarilumab for patients with severe or critical COVID-19 (13).

315

Table 1: Trial Characteristics									
Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Type of care	Severity	Detailed ventilation (%)	Treatments (dose and duration)
IL-6 Receptor Blocker: Tocilizumab									
ARCHITECTS	Data from meta-analysis NCT04412772	21	United States	61.5	57.1	Inpatient	Mild/Moderate (0%) Severe (100%)	NR	tocilizumab placebo
CORIMUNO-TOCI-ICU	Data from meta-analysis NCT04331808	92	France	64.2	71.7	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (100%)	High-flow, NIV, or IV (100.0%)	tocilizumab standard care
COV-AID	Data from meta-analysis NCT04330638	230	Belgium	63.6	77.4	Inpatient	Mild/Moderate (0%) Severe (100%)	NR	tocilizumab siltuximab standard care
COVIDOSE2-SSA	Data from meta-analysis NCT04479358	28	United States	65	67.9	Inpatient	Mild/Moderate (0%) Severe (100%)	Mechanical ventilation (0.0%)	tocilizumab tocilizumab standard care
COVIDSTORM	Data from meta-analysis NCT04577534	39	Finland	65.7	53.9	Inpatient	Mild/Moderate (0%) Severe (100%)	NR	tocilizumab standard care
COVIT0Z	Data from meta-analysis NCT04435717	26	Spain	57.5	65.4	Inpatient Intensive care (0.0%)	Mild/Moderate (100%) Severe (100%)	NR	tocilizumab tocilizumab standard care
Hermine, 2021 (26) CORIMUNO-TOCI 1	Published NCT04331808	131	France	64	67.7	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%) Critical (0%)	Supplemental oxygen (100.0%) NIV or IV (0.0%)	tocilizumab standard care
HMO-020-0224	Data from meta-analysis NCT04377750	54	Israel	63.1	68.5	Inpatient	Mild/Moderate (0%) Severe (100%)	NR	tocilizumab placebo

Horby, 2021 (6) RECOVERY	Published NCT04381936	4116	United Kingdom	63.6	67.3	Inpatient	Mild/Moderate (0%) Severe (100%)	Supplemental oxygen (45.4%) High-flow or NIV (41.0%) IV (13.7%)	tocilizumab standard care
ImmCoVA	Data from meta-analysis NCT04412291	49	Sweden	NR	NR	Inpatient	Mild/Moderate (0%) Severe (100%)	IV (0.0%)	tocilizumab standard care
REMDACTA	Data from meta-analysis NCT04409262	640	Spain, United States, Brazil, Russia	60.3	63.3	Inpatient	Mild/Moderate (0%) Severe (100%)	NR	tocilizumab placebo
Rosas, 2021 (27) COVACTA	Published NCT04320615	452	Canada, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States	60.8	69.9	Inpatient Intensive care (56.4%)	Mild/Moderate (0%) Severe (100%) Critical (0%)	NIV or IV (37.7%)	tocilizumab placebo
Rutgers, 2021 (28) PreToVid	Pre-print NL8504	354	Netherlands	66.5	67	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%)	Supplemental oxygen (96.6%)	tocilizumab standard care

Soin, 2021 (29) COVINTOC	Published CTRI/2020/05/02 5369	180	India	55	84.9	Inpatient	Mild/Moderate (49.2%) Severe (50.8%)	Supplemental oxygen (89.9%) NIV (26.8%) IV (5.0%)	tocilizumab standard care
Stone, 2020 (30) BACC BAY	Published NCT04356937	243	United States	59.9	58	Inpatient Intensive care (4.5%)	Mild/Moderate (0%) Severe (100%) Critical (0%)	Supplemental oxygen (79.8%) High-flow or NIV (4.1%) IV (0.4%)	tocilizumab placebo
Salama, 2021 (31) EMPACTA	Published NCT04372186	388	United States, Peru, Brazil, Kenya, South Africa, Mexico	55.9	59.1	Inpatient Intensive care (15.4%)	Mild/Moderate (0%) Severe (100%) Critical (0%)	Mechanical ventilation (0.0%)	tocilizumab placebo
Salvarani, 2020 (32) RCT-TCZ-COVID-19	Published NCT04346355	126	Italy	60	61.1	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%) Critical (0%)	NIV or IV (0.0%)	tocilizumab standard care
TOCOVID	Data from meta-analysis EudraCT2020-001442-19	270	Spain	53	63.7	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (100%)	NR	tocilizumab standard care
Talaschian, 2021 (33)	Pre-print IRCT20081027001411N4	40	Iran	61.7	52.8	Inpatient	Mild/Moderate (0%) Severe (100%) Critical (0%)	Nasal cannula (50.0%) Simple mask (30.6%) Reservoir mask	tocilizumab standard care

								(11.1%) Niv (8.3%) Iv (0.0%)	
Veiga, 2021 (34) TOCIBRAS	Published NCT04403685	129	Brazil	57.5	68.2	Inpatient	Mild/Moderate (0%) Severe (100%)	Supplemental oxygen (51.9%) High-flow or NIV (31.8%) IV (16.3%)	tocilizumab standard care
IL-6 Receptor Blocker: Sarilumab									
CORIMUNO-SARI-1	Data from meta-analysis NCT04324073	144	France	62.3	75	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%)	NR	sarilumab standard care
CORIMUNO-SARI-ICU	Data from meta-analysis NCT04324073	81	France	61.6	76.5	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (100%)	NR	sarilumab standard care
SARCOVID	Data from meta-analysis NCT04357808	30	Spain	61.7	66.7	Inpatient	Mild/Moderate (0%) Severe (100%)	Mechanical ventilation (0.0%)	sarilumab standard care
SARICOR	Data from meta-analysis EudraCT2020-001531-27	80	Spain	59.4	71.2	Inpatient	Mild/Moderate (0%) Severe (100%)	Mechanical ventilation (0.0%)	sarilumab sarilumab standard care
SARTRE	Data from meta-analysis EudraCT2020-002037-15	140	Spain	58.4	72.9	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%)	Mechanical ventilation (0.0%)	sarilumab standard care
Sivapalasingam, 2021 (35) (Phase 2)	Pre-print NCT04315298	457	United States	58.7	72.4	Inpatient	Mild/Moderate (0%) Severe (50.5%) Critical (49.5%)	Supplemental oxygen (27.6%) High-flow,	sarilumab (200 mg) sarilumab (400 mg) placebo

Sarilumab-COVID-19								NIV, or IV (49.5%)	
Sivapalasingam, 2021 (35) (Phase 3, cohort 1) Sarilumab-COVID-19	Pre-print NCT04315298	1365	United States	61.7	64.5	Inpatient	Mild/Moderate (0%) Severe (45%) Critical (55%)	Supplemental oxygen (27.0%) IV (21.8%)	sarilumab (200 mg) sarilumab (400 mg) placebo
Sivapalasingam, 2021 (35) (Phase 3, cohort 2) Sarilumab-COVID-19	Pre-print NCT04315298	31	United States	48.7	71	Inpatient	Mild/Moderate (0%) Severe (0%) Critical (100%)	IV (100.0%)	sarilumab (800 mg) placebo
Sivapalasingam, 2021 (35) (Phase 3, cohort 3) Sarilumab-COVID-19	Pre-print NCT04315298	8	United States	60.8	62.5	Inpatient	Mild/Moderate (0%) Severe (0%) Critical (100%)	High-flow or NIV (100.0%) IV (0.0%)	sarilumab (800 mg) placebo
Lescure, 2021 (36)	Published NCT04327388; Eudra CT (2020-001162-12), WHO (U1111-1249-6021)	420	Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, Spain	59	62.7	Inpatient Intensive care (35.6%)	Mild/Moderate (0%) Severe (60.6%) Critical (38.9%)	Nasal cannula (42.1%) Face mask (26.7%) Nonrebreather face mask (10.5%) High-flow (6.2%) NIV (1.7%) IV (11.5%) Other (1.2%)	sarilumab (400 mg) sarilumab (200 mg) placebo
IL-6 Receptor Blockers: Tocilizumab/Sarilumab									

Gordon, 2021 (50) REMAP-CAP	Published NCT02735707	798	United Kingdom, Netherlands, Australia, New Zealand, Ireland, Saudi Arabia	61.4	72.6	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (0%) Critical (100%)	High-flow (28.8%) NIV (41.5%) IV (29.4%)	tocilizumab standard care (for tocilizumab) sarilumab standard care (for sarilumab)
Gordon, 2021 (50) REMAP-CAP	Data from authors NCT02735707	1020	United Kingdom, Netherlands, Australia, New Zealand, Ireland, Saudi Arabia	NR	NR	Inpatient	Mild/Moderate (0%) Severe (0%) Critical (100%)	NR	tocilizumab sarilumab
IL-6 Receptor Blockers versus Corticosteroids									
Rashad, 2021 (48)	Published CT04519385 (19/08/2020)	149	Egypt	62.5	56.9	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (100%) Critical (100%)	NIV (64.2%) IV (35.8%)	tocilizumab dexamethasone
SILCOR	Data from meta-analysis EudraCT2020-001413-20	158	Spain	62	65.2	Inpatient	Mild/Moderate (0%) Severe (100%) Critical (0%)	NR	siltuximab corticosteroids
STORM	Data from meta-analysis NCT04345445	59	Malaysia	53.2	76.3	Inpatient Intensive care (0.0%)	Mild/Moderate (100%) Severe (0%) Critical (0%)	Mechanical ventilation (0.0%)	tocilizumab dexamethasone
Corticosteroids									

Angus, 2020 (37) REMAP-CAP	Published NCT02735707	403	Australia, Canada, Ireland, France, Netherlands, New Zealand, United Kingdom, United States	59.9	71.1	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (100%)	High-flow (14.6%) NIV (29.7%) IV (55.5%) ECMO (0.8%)	hydrocortisone (fixed- dose) hydrocortisone (shock- dependent) standard care
Corral-Gudino, 2021 (38) GLUCOCOVID	Published 2020-001934-37	64	Spain	69.8	60.9	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%) Critical (0%)	Mechanical ventilation (0.0%)	methylprednisolone standard care
Dequin, 2020 (39) CAPECOVID	Published NCT02517489	149	France	62.2	69.8	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (0%) Critical (100%)	Nonrebreath ing mask with a reservoir bag (6.0%) High-flow (12.8%) NIV or IV (81.2%)	hydrocortisone placebo
Edalatifard, 2020 (40)	Published IRCT20200404046 947N1	68	Iran	58.5	62.9	Inpatient	Mild/Moderate (0%) Severe (100%) Critical (0%)	Nasal cannula (21.0%) Simple mask (11.3%) Reserve mask (29.0%) NIV (37.1%)	methylprednisolone standard care

Farahani, 2020 (41)	Pre-print IRCT20200406046963N1	29	Iran	64	65.5	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (100%)	NR	methylprednisolone, prednisolone standard care
Horby, 2021 (42) RECOVERY	Published NCT04381936	6425	United Kingdom	66.2	63.6	Inpatient	NR	Supplemental oxygen or NIV (60.4%) IV or ECMO (15.7%)	dexamethasone standard care
Jamaati, 2021 (43)	Published IRCT20151227025726N17	50	Iran	62	72	Inpatient	Mild/Moderate (0%) Severe (100%)	NR	dexamethasone standard care
Jeronimo, 2020 (44) Metcovid	Published NCT04343729	416	Brazil	55	65.3	Inpatient Intensive care (35.4%)	NR	Non-invasive oxygen (47.5%) Invasive mechanical ventilation (33.9%)	methylprednisolone placebo
Steroids-SARI	Data from meta-analysis NCT04244591	47	China	64.5	74.5	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (0%) Critical (100%)	Mechanical ventilation (57.5%)	methylprednisolone standard care
DEXA-COVID 19	Data from meta-analysis NCT04325061	19	Spain	60.7	68.4	NR	Mild/Moderate (0%) Severe (0%) Critical (100%)	IV (100.0%)	dexamethasone standard care
COVID STEROID	Data from meta-analysis NCT04348305	29	Denmark	59.4	79.3	NR	Mild/Moderate (0%) Severe (0%) Critical (100%)	Mechanical ventilation (51.7%)	hydrocortisone placebo

Tang, 2021 (45)	Published NCT04273321	86	China	56	47.7	Inpatient Intensive care (0.0%)	Mild/Moderate (0%) Severe (100%)	Nasal cannula (70.9%)	methylprednisolone standard care
Tomazini, 2020 (46) CoDEX	Published NCT04327401	299	Brazil	61.4	62.5	Inpatient Intensive care (100.0%)	Mild/Moderate (0%) Severe (0%) Critical (100%)	Pressure control ventilation (44.5%) Volume control ventilation (46.5%) Other (9.0%)	dexamethasone standard care
Vaira, 2020 (47)	Published	18	Italy	42.1	38.9	Outpatient Intensive care (0.0%)	Mild/Moderate (100%) Severe (0%) Critical (0%)	NR	corticosteroids standard care

318


319

Table 2: Summary of findings for network meta-analysis comparing tocilizumab and sarilumab, alone or in combination with corticosteroids

Comparison	OR (95% CI)	Absolute effect estimates		Certainty of the Evidence (Quality of evidence)	Plain text summary
		Intervention 1	Intervention 2		
Tocilizumab vs Standard care	1.12 (95% CI: 0.91 – 1.38)	150 per 1,000	130 per 1,000	Low (risk of bias, imprecision)	Tocilizumab may increase mortality compared to standard care.
Sarilumab vs Standard care	1.07 (95% CI: 0.81 – 0.40)	141 per 1,000	130 per 1,000	Low (risk of bias, imprecision)	Sarilumab may increase mortality compared to standard care.
Corticosteroids vs Standard care	0.84 (95% CI: 0.75 – 0.93)	101 per 1,000	130 per 1,000	Moderate (risk of bias)	Corticosteroids probably reduce mortality compared to standard care.
Sarilumab vs. Tocilizumab	0.95 (95% CI: 0.68 – 1.35)	141 per 1,000	150 per 1,000	Very Low (risk of bias, imprecision)	We are uncertain of the effects of sarilumab compared to tocilizumab.
Tocilizumab and Corticosteroids vs Corticosteroids alone	0.79 (95% CI: 0.70 – 0.88)	66 per 1,000	101 per 1,000	Moderate (risk of bias)	Tocilizumab, in combination with corticosteroids, probably reduces

		(95% CI: -51.80 to -18.23)		mortality compared to corticosteroids alone.
Sarilumab and Corticosteroids vs Corticosteroids alone	0.73 (95% CI: 0.58 – 0.92)	58 per 1,000 101 per 1,000 Difference: 42.73 fewer per 1,000 (95% CI: -72.61 to -12.00)	Low (risk of bias, imprecision)	Sarilumab, in combination with corticosteroids, may reduce mortality compared to corticosteroids alone
Tocilizumab and Corticosteroids vs Sarilumab and Corticosteroids	1.07 (95% CI: 0.86 – 1.34)	66 per 1,000 58 per 1,000 Difference: 8.19 more per 1,000 (95% CI: -20.49 to 34.96)	Low (risk of bias, imprecision)	Tocilizumab, in combination with corticosteroids, may have similar effects to reduce mortality compared with sarilumab in combination with corticosteroids.

321 **Figure 1: PRISMA diagram**




322

323

324

325

326 **Figure 2: Network diagram** (nodes are weighted according to the number of studies evaluating each
327 treatment and edges weighted according to the precision (inverse variance) of the direct estimate for
328 each pairwise comparison).



329

330 **Figure 3: Risk of bias of trials included in the network meta-analysis**

Author (if published)	Trial (trial registration)	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	
Tocilizumab							
	ARCHITECTS (NCT04412772)	●	●	●	●	●	Low risk of bias
	CORIMUNO-TOCI-ICU (NCT04331808)	●	●	●	●	●	Probably low risk of bias
	COV-AID (NCT04330638)	●	●	●	●	●	Probably high risk of bias
	COVIDOSE2-SSA (NCT04479358)	●	●	●	●	●	High risk of bias
	COVIDSTORM (NCT04577534)	●	●	●	●	●	
	COVITOX (NCT04435717)	●	●	●	●	●	
Hermine, 2020	CORIMUNO-TOCI-1 (NCT04331808)	●	●	●	●	●	
	HMO-020-0224 (NCT04377750)	●	●	●	●	●	
Horby, 2021	RECOVERY (NCT04381936)	●	●	●	●	●	
	ImmCoVA (NCT04412291)	●	●	●	●	●	
	REMDACTA (NCT04409262)	●	●	●	●	●	
Rosas, 2021	COVACTA (NCT04320615)	●	●	●	●	●	
Rutgers, 2021	PreToVid (NL8504)	●	●	●	●	●	
Stone, 2020	BACC Bay (NCT04356937)	●	●	●	●	●	
Salama, 2020	EMPACTA (NCT04372186)	●	●	●	●	●	
Veiga, 2021	TOCIBRAS (NCT04403685)	●	●	●	●	●	
Sarilumab							
	CORIMUNO-SARI-1 (NCT04324073)	●	●	●	●	●	
	CORIMUNO-SARI-ICU (NCT04324073)	●	●	●	●	●	
	SARCOVID (NCT04357808)	●	●	●	●	●	
	SARICOR (EudraCT2020-001531-27)	●	●	●	●	●	
	SARTRE (EudraCT2020-002037-15)	●	●	●	●	●	
Sivapalasingam, 2021	Sarilumab-COVID-19 (NCT04315298)	●	●	●	●	●	
Tocilizumab/Sarilumab							
Gordon, 2021	REMAP-CAP (NCT02735707)	●	●	●	●	●	
Tocilizumab/Corticosteroids							
Rashad, 2021	(CT04519385 (19/08/2020))	●	●	●	●	●	
Corticosteroids							
Angus, 2020	REMAP-CAP (NCT02735707)	●	●	●	●	●	
Corral-Gudino, 2020	GLUCCOCOVID (2020-001934-37)	●	●	●	●	●	
Dequin, 2020	CAPECOVID (NCT02517489)	●	●	●	●	●	
Edaltifard, 2020	(IRCT20200404046947N1)	●	●	●	●	●	
Horby, 2020	RECOVERY (NCT04381936)	●	●	●	●	●	
Jamaati, 2021	(IRCT20151227025726N17)	●	●	●	●	●	
Jeronimo, 2020	Metcovid (NCT04343729)	●	●	●	●	●	
	DEXA-COVID 19 (NCT04325061)	●	●	●	●	●	
	COVID STEROID (NCT04348305)	●	●	●	●	●	
	Steroids-SARI (NCT04244591)	●	●	●	●	●	
Tang, 2021	Tang_2 (NCT04273321)	●	●	●	●	●	
Tomazini, 2020	CoDEX (NCT04327401)	●	●	●	●	●	

331

332 References

- 333 1. COVID-19 Worldometer [Available from: <https://www.worldometers.info/coronavirus/>.
- 334 2. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and
335 network meta-analysis. *Bmj*. 2020;370:m2980.
- 336 3. Pitre T, Jones A, Su J, et al. Inflammatory biomarkers as independent prognosticators of 28-day mortality
337 for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study. *Intern
338 Emerg Med*. 2021:1-10.
- 339 4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
340 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-13.
- 341 5. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19
342 severity and survival. *Nat Med*. 2020;26(10):1636-43.
- 343 6. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled,
344 open-label, platform trial. *Lancet*. 2021;397(10285):1637-45.
- 345 7. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients
346 with Covid-19. *N Engl J Med*. 2021;384(16):1491-502.
- 347 8. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-
348 19. *N Engl J Med*. 2020;383(24):2333-44.
- 349 9. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With
350 COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med*.
351 2021;181(1):32-40.
- 352 10. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in
353 Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med*.
354 2021;181(1):24-31.
- 355 11. Shankar-Hari M, Vale C, Godolphin P, et al. Association of administration of interleukin-6 antagonists
356 with mortality and other outcomes among hospitalized patients with COVID-19: a prospective meta-
357 analysis. *JAMA*. 2021.
- 358 12. Verma AA, Pai M, Saha S, et al. Managing drug shortages during a pandemic: tocilizumab and COVID-
359 19. *Cmaj*. 2021;193(21):E771-e6.
- 360 13. Rochwerg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. *Bmj*.
361 2020;370:m3379.
- 362 14. Marshall IJ, Noel-Storr A, Kuiper J, et al. Machine learning for identifying Randomized Controlled Trials:
363 An evaluation and practitioner's guide. *Res Synth Methods*. 2018;9(4):602-14.
- 364 15. Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids
365 and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *Jama*. 2020;324(13):1330-41.
- 366 16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.
367 *Bmj*. 2019;366:l4898.
- 368 17. Turner RM, Jackson D, Wei Y, et al. Predictive distributions for between-study heterogeneity and
369 simple methods for their application in Bayesian meta-analysis. *Stat Med*. 2015;34(6):984-98.
- 370 18. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS
371 One*. 2013;8(10):e76654.
- 372 19. Centers for Disease Control and Prevention. COVIDView. A weekly surveillance summary of U.S COVID-
373 19 activity 2020 [Available from: [https://www.cdc.gov/coronavirus/2019-ncov/covid-
374 data/covidview/index.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html).
- 375 20. Centers for Disease Control and Prevention. Daily updates of totals by week and state: provisional
376 death counts for coronavirus disease 2019 (COVID-19) 2020 [Available from:
377 <https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm>.
- 378 21. ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium). COVID-19
379 Report: 08 June 2020. medRxiv 2020.

- 380 22. Hultcrantz M, Rind D, Akl EA, et al. The GRADE Working Group clarifies the construct of certainty of
381 evidence. *J Clin Epidemiol.* 2017;87:4-13.
- 382 23. Puhan MA, Schönemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality
383 of treatment effect estimates from network meta-analysis. *Bmj.* 2014;349:g5630.
- 384 24. Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, et al. GRADE approach to rate the certainty
385 from a network meta-analysis: addressing incoherence. *J Clin Epidemiol.* 2019;108:77-85.
- 386 25. Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the
387 certainty in estimates from a network meta-analysis. *J Clin Epidemiol.* 2018;93:36-44.
- 388 26. Hermine O, Mariette X, Tharaux P-L, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized
389 With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Internal Medicine.*
390 2020.
- 391 27. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19
392 Pneumonia. *N Engl J Med.* 2021.
- 393 28. Rutgers AaW, Peter E. and van der Holt, Bronno and Postma, Simone and van Vonderen, Marit G.A.
394 and Piersma, Djura P. and Postma, Douwe and van den Berge, Maarten and Jong, Eefje and de Vries,
395 Marten and van der Burg, Leonie and Huugen, Dennis and van der Poel, Marjolein and Kampschreur, Linda
396 M. and Nijland, Marcel and Strijbos, Jaap H. and Tamminga, Menno and Mutsaers, Pim G. N. J. and Schol-
397 Gelok, Suzanne and Dijkstra-Tiekstra, Margriet and Sidorenkov, Grigory and Vincenten, Julien and van
398 Geffen, Wouter H. and Knoester, Marjolein and Kosterink, Jos and Gans, Reinold and Stegeman, Coen and
399 Huls, Gerwin and van Meerten, Tom, . Timely Administration of Tocilizumab Improves Survival of
400 Hospitalized COVID-19 Patients. . Available at SSRN: <https://ssrncom/abstract=3834311> or
401 <http://dxdoiorg/102139/ssrn3834311>. 2021.
- 402 29. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients
403 in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-
404 label, multicentre, randomised, controlled, phase 3 trial. (2213-2619 (Electronic)).
- 405 30. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-
406 19. *New England Journal of Medicine.* 2020.
- 407 31. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J*
408 *Med.* 2021;384(1):20-30.
- 409 32. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in
410 Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA Internal Medicine.*
411 2020.
- 412 33. Talaschian M, Akhtari M, Mahmoudi M, et al. Tocilizumab Failed to Reduce Mortality in Severe COVID-
413 19 Patients: Results From a Randomized Controlled Clinical Trial. *Respiratory Research.* 2021.
- 414 34. Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients
415 with severe or critical coronavirus disease 2019: randomised controlled trial. *BMJ.* 2021;372:n84.
- 416 35. Sivapalasingam S, Lederer DJ, Bhore R, et al. A Randomized Placebo-Controlled Trial of Sarilumab in
417 Hospitalized Patients with Covid-19. *medRxiv.* 2021:2021.05.13.21256973.
- 418 36. Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical
419 COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Respiratory*
420 *medicine.* 2021;9(5):522-32.
- 421 37. The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and
422 Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain
423 Randomized Clinical Trial. *Jama.* 2020;02:02.
- 424 38. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with
425 COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID). *Wiener klinische Wochenschrift.*
426 2021:1-9.

- 427 39. Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory
428 Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *Jama*. 2020;02:02.
- 429 40. Edalatfard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for
430 hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. *The European*
431 *respiratory journal*. 2020.
- 432 41. Farahani RH MR, Nezami-Asl A et al. . Evaluation of the Efficacy of Methylprednisolone Pulse Therapy
433 in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized, Clinical Trial,. 09
434 September 2020, PREPRINT (Version 1) available at Research Square [[https://doi.org/10.21203/rs-
435 66909/v1](https://doi.org/10.21203/rs.3.rs-66909/v1)]. 2020.
- 436 42. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J*
437 *Med*. 2021;384(8):693-704.
- 438 43. Jamaati H, Hashemian SM, Farzanegan B, et al. No clinical benefit of high dose corticosteroid
439 administration in patients with COVID-19: A preliminary report of a randomized clinical trial. *Eur J*
440 *Pharmacol*. 2021;897:173947.
- 441 44. Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as Adjunctive Therapy for Patients
442 Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.
443 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
- 444 45. Tang X, Feng YM, Ni JX, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-
445 Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control
446 Trial. *Respiration; international review of thoracic diseases*. 2021:1-11.
- 447 46. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free
448 in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX
449 Randomized Clinical Trial. *Jama*. 2020;02:02.
- 450 47. Vaira LA, Hopkins C, Petrocelli M, et al. Efficacy of corticosteroid therapy in the treatment of long-
451 lasting olfactory disorders in COVID-19 patients. *Rhinology*. 2021;59(1):21-5.
- 452 48. Rashad A, Mousa S, Nafady-Hego H, et al. Short term survival of critically ill COVID-19 Egyptian patients
453 on assisted ventilation treated by either Dexamethasone or Tocilizumab. *Sci Rep*. 2021;11(1):8816.
- 454 49. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association
455 Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With
456 COVID-19: A Meta-analysis. *Jama*. 2020;02:02.
- 457 50. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients
458 with Covid-19. *N Engl J Med*. 2021.

459